Medullary Thyroid Cancer: Clinical Trials

13 trials for Medullary Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 terminated, 3 unknown, 2 completed. 13 Phase 2, 9 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Active not recruiting 3, Terminated 3, Unknown 3, Completed 2, Recruiting 1, Withdrawn 1
Phase 19Unknown 3, Active not recruiting 2, Terminated 2, Completed 1, Recruiting 1

Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer
Phase 1 / Phase 2RecruitingUniversity of Arizona302025-09-082026-10-06
A Study of TY-1091 in Patients With Advanced Solid Tumors
TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownTYK Medicines, Inc2482023-04-242024-01-30
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownShouyao Holdings (Beijing) Co. LTD1842021-04-232023-04-12
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Selpercatinib - Solid Tumor, Medullary Thyroid Cancer
Phase 2Active not recruitingEli Lilly and Company772020-03-162026-08-07
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2TerminatedTurning Point Therapeutics, Inc.412019-12-062024-06-13
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Ponatinib - Medullary Thyroid Cancer
Phase 2WithdrawnAntonio Fojo2019-07-262021-10-13
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis
Phase 1 / Phase 2Active not recruitingEli Lilly and Company362019-06-132026-01-06
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2Active not recruitingEli Lilly and Company8572017-05-022026-04-16
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2CompletedHoffmann-La Roche5902017-03-172025-05-31
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer
Phase 1 / Phase 2TerminatedAbbVie2002016-09-232020-10-19
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
CASAD - Diarrhea, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownSalient Pharmaceuticals Incorporated102012-11-012012-12-03
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
SOM230 alone or in combination with RAD001. - Medullary Thyroid Cancer
Phase 2CompletedFederico II University192012-02-012016-04-25
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
Lithium carbonate - Medullary Thyroid Cancer
Phase 2TerminatedUniversity of Wisconsin, Madison52008-01-012019-12-09

Narrower conditions

Carcinoma, Medullary (13)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Thyroid Neoplasms (5)  ·  Lung Neoplasms (4)  ·  Neoplasms (4)  ·  Bronchial Neoplasms (3)  ·  Carcinoma, Bronchogenic (3)  ·  Colonic Neoplasms (3)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Head and Neck Neoplasms (3)  ·  Lung Diseases (3)  ·  Neoplasms by Site (3)  ·  Respiratory Tract Diseases (3)  ·  Respiratory Tract Neoplasms (3)

Broader conditions

Neoplasms, Ductal, Lobular, and Medullary (13)  ·  Adenocarcinoma (12)  ·  Carcinoma (12)  ·  Carcinoma, Neuroendocrine (12)  ·  Neoplasms by Histologic Type (12)  ·  Neoplasms, Germ Cell and Embryonal (12)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Neoplasms, Nerve Tissue (12)  ·  Neuroectodermal Tumors (12)  ·  Neuroendocrine Tumors (12)  ·  Neoplasms (9)  ·  Neoplasms by Site (5)  ·  Bronchial Neoplasms (4)  ·  Carcinoma, Bronchogenic (4)  ·  Lung Diseases (4)

Interventions

selpercatinib (3)  ·  Calcium Aluminosilicate (1)  ·  Dexamethasone (1)  ·  Everolimus (1)  ·  Lithium Carbonate (1)  ·  pasireotide (1)  ·  ponatinib (1)  ·  pralsetinib (1)  ·  rovalpituzumab tesirine (1)

Sponsors

Eli Lilly and Company (3)  ·  AbbVie (1)  ·  Antonio Fojo (1)  ·  Federico II University (1)  ·  Hoffmann-La Roche (1)  ·  Salient Pharmaceuticals Incorporated (1)  ·  Shouyao Holdings (Beijing) Co. LTD (1)  ·  TYK Medicines, Inc (1)  ·  Turning Point Therapeutics, Inc. (1)  ·  University of Arizona (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (8)  ·  China (4)  ·  Italy (4)  ·  South Korea (4)  ·  France (3)  ·  Germany (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Denmark (2)  ·  Hong Kong (2)  ·  Japan (2)  ·  Singapore (2)  ·  Taiwan (2)

Top investigators

Annamaria Colao (1)  ·  Antonio Fojo, MD (1)  ·  Charles Hsu, MD (1)  ·  Herbert Chen, MD (1)  ·  Ricklie Julian, MD (1)  ·  Yinghui Sun, PhD (1)

Results publications

PMID 37934000, PMID 29572709, PMID 32372416, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35923928, PMID 35930972, PMID 35962206, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37282666, PMID 37315261, PMID 37655205, PMID 37916501, PMID 38009200, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39489747, PMID 39759832, PMID 39983053, PMID 40639400, PMID 41886723, PMID 42874021

NIH funding

2016 (1), 2017 (1), 2019 (1), 2023 (1)